# Vedanta Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vedanta-biosciences

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.vedantabio.com
- Total disclosed funding: $122M
- Latest round: Series D (Jul 16, 2021)
- Investors on record: 21

## About

Vedanta Biosciences, Inc. is a biotechnology company focused on developing innovative Live Biotherapeutic Products (LBPs) for gastrointestinal diseases, aiming to restore gut health using defined bacterial consortia.Founded in 2010 and headquartered in Cambridge, US, Vedanta Biosciences, Inc. specializes in biotherapeutic solutions for gastrointestinal issues. The company has raised a total of USD 106.5 mn, with its most recent funding round occurring in April 2023, involving multiple investors including AMR Action Fund and the Bill & Melinda Gates Foundation. The firm was founded by Bernat Olle, who also serves as CEO, and has successfully completed eight deals to date.Vedanta Biosciences, Inc. specializes in the development of first-in-class Live Biotherapeutic Products (LBPs) designed to address serious gastrointestinal diseases through the utilization of defined consortia of bacteria. These innovative products aim to restore gut microbiota balance, targeting conditions such as inflammatory bowel disease (IBD) and recurrent Clostridium difficile infections. By leveraging the ability of these biotherapeutic agents to stimulate immune responses, Vedanta seeks to provide effective treatment options for patients suffering from gut dysbiosis, a noted contributor to various gastrointestinal ailments. The company is conducting clinical trials to evaluate the efficacy and safety of its leading candidates, including VE202 and VE303. These products are primarily aimed at markets in North America and Europe, where the demand for advanced gastrointestinal therapeutics is growing among healthcare providers and patients.The revenue model for Vedanta Biosciences operates primarily through partnerships and collaborations with healthcare institutions and pharmaceutical companies, focusing on clinical trial agreements and product development initiatives. The company engages in B2B transactions with healthcare providers and research institutions that seek innovative treatment options for gastrointestinal diseases. Specific pricing structures for its products are not disclosed, but revenue is generated from milestone payments, royalties, and potential product sales once the drugs receive regulatory approval. Vedanta's flagship products, including VE202 and VE303, are central to its revenue strategy as the company prepares to bring these therapeutics to market, aligning with its mission to improve patient outcomes in gastrointestinal health. In August 2026, Vedanta Biosciences, Inc. raised USD 40 million in venture funding co-led by AMR Action Fund and BNP Paribas Asset Management - Fund of funds. The round was part of a larger USD 60 million equity and grant funding.

## Funding rounds

- Series D, Jul 16, 2021, $68M — Seventure Partners, PureTech Ventures, Magnetar Capital, JSR Corporation, Verition Fund Management, Rock Springs Capital, Shumway Capital, SymBiosis LLC, Skyviews Life Science, Fosun Health Capital
- Series C, Sep 23, 2019, $8M — Shinhan Securities, Partners Investment, Shinhan Capital, SV Investment, QUAD Ventures, SymBiosis LLC, FC Capital - China
- Series C, May 13, 2019, $19M — Shumway Capital, JSR, SymBiosis LLC
- Series C, Dec 24, 2018, $27M — Seventure Partners, Bristol-Myers Squibb Company, Bill & Melinda Gates Foundation, Rock Springs Capital, Invesco Asset Management, PureTech Health plc

## Investors

- Seventure Partners (https://capitalatlas.ai/funds/seventure-partners) — Series C, Series D
- Bristol-Myers Squibb Company — Series C
- Bill & Melinda Gates Foundation — Series C
- Rock Springs Capital — Series C, Series D
- Invesco Asset Management — Series C
- PureTech Health plc — Series C
- Shumway Capital (https://capitalatlas.ai/funds/shumway-capital) — Series C, Series D
- JSR — Series C
- SymBiosis LLC — Series C, Series D
- Shinhan Securities (https://capitalatlas.ai/funds/shinhan-securities) — Series C
- Partners Investment (https://capitalatlas.ai/funds/partners-investment) — Series C
- Shinhan Capital (https://capitalatlas.ai/funds/shinhan-capital) — Series C
- SV Investment (https://capitalatlas.ai/funds/sv-investment) — Series C
- QUAD Ventures (https://capitalatlas.ai/funds/quad-ventures) — Series C
- FC Capital - China (https://capitalatlas.ai/funds/fc-capital-china) — Series C
- PureTech Ventures — Series D
- Magnetar Capital (https://capitalatlas.ai/funds/magnetar-capital) — Series D
- JSR Corporation — Series D
- Verition Fund Management — Series D
- Skyviews Life Science (https://capitalatlas.ai/funds/skyviews-life-science) — Series D
- Fosun Health Capital (https://capitalatlas.ai/funds/fosun-health-capital) — Series D